研究者業績

濱 進

Susumu Hama

基本情報

所属
武蔵野大学 薬学部 薬学科
学位
博士(薬学)(北海道大学)

研究者番号
60438041
J-GLOBAL ID
201901007919942126
researchmap会員ID
B000349317

委員歴

 1

論文

 59
  • Kitamura K., Matsui R., Itagaki N., Takeuchi Y., Fukuda H., Tanaka KI, Hama S.
    Nanomaterials (Basel). 15(22) 1695 2025年11月  査読有り最終著者責任著者
  • Funayama R., Toratani A., Uehara Y., Kinoshita R., Shimada M., Imai R., Shimoda M., Kawahara M., Hama S., Tanaka KI
    Environ Toxicol. 41(2) 121-130 2025年8月  査読有り
  • Susumu Hama, Takayuki Nishi, Eitaro Isono, Shoko Itakura, Yutaka Yoshikawa, Akinori Nishimoto, Satoko Suzuki, Naoko Kirimura, Hiroaki Todo, Kentaro Kogure
    Cancer science 113(5) 1779-1788 2022年5月  査読有り筆頭著者責任著者
    Intraperitoneal administration of anticancer nanoparticles is a rational strategy for preventing peritoneal dissemination of colon cancer due to the prolonged retention of nanoparticles in the abdominal cavity. However, instability of nanoparticles in body fluids causes inefficient retention, reducing its anticancer effects. We have previously developed anticancer nanoparticles containing tocopheryl succinate, which showed high in vivo stability and multifunctional anticancer effects. In the present study, we have demonstrated that peritoneal dissemination derived from colon cancer was prevented by intraperitoneal administration of tocopheryl succinate nanoparticles. The biodistribution of tocopheryl succinate nanoparticles was evaluated using inductively coupled plasma mass spectroscopy and imaging analysis in mice administered quantum dot encapsulated tocopheryl succinate nanoparticles. Intraperitoneal administration of tocopheryl succinate nanoparticles showed longer retention in the abdominal cavity than by its intravenous (i.v.) administration. Moreover, due to effective biodistribution, tumor growth was prevented by intraperitoneal administration of tocopheryl succinate nanoparticles. Furthermore, the anticancer effect was attributed to the inhibition of cancer cell proliferation and improvement of the intraperitoneal microenvironment, such as decrease in the levels of vascular endothelial growth factor A, interleukin 10, and M2-like phenotype of tumor-associated macrophages. Collectively, intraperitoneal administration of tocopheryl succinate nanoparticles is expected to have multifaceted antitumor effects against colon cancer with peritoneal dissemination.
  • Susumu Hama, Naoko Kirimura, Aki Obara, Hirokatsu Takatsu, Kentaro Kogure
    Molecules 27(4) 1425 2022年  査読有り招待有り筆頭著者
    Anti-rheumatoid arthritis (RA) effects of α-tocopherol (α-T) have been shown in human patients in a double-blind trial. However, the effects of α-T and its derivatives on fibroblast-like synoviocytes (FLS) during the pathogenesis of RA remain unclear. In the present study, we compared the expression levels of genes related to RA progression in FLS treated with α-T, succinic ester of α-T (TS), and phosphate ester of α-T (TP), as determined via RT-PCR. The mRNA levels of interleukin (IL)-6, tumor necrosis factor-α (TNF-α), matrix metalloproteinase (MMP)-3, and MMP-13 were reduced by treatment with TP without cytotoxicity, while α-T and TS did not show such effects. Furthermore, intraperitoneal injection of TP ameliorated the edema of the foot and joint and improved the arthritis score in laminarin-induced RA model mice. Therefore, TP exerted anti-RA effects through by inhibiting RA-related gene expression.
  • Susumu Hama, Mika Sakai, Shoko Itakura, Eiji Majima, Kentaro Kogure
    Biochemistry and Biophysics Reports 27 101067-101067 2021年9月  査読有り筆頭著者責任著者

MISC

 48

書籍等出版物

 15

講演・口頭発表等

 12

共同研究・競争的資金等の研究課題

 9

メディア報道

 1